Multi-drug resistance in malaria under combination therapy

In the battle against malaria, Wageningen UR Food & Biobased Research worked together with partners from Africa and Europe on a research project to assess the specific markers and develop innovative, rapid and simple diagnostics. This project is funded by the European Commission (contract Health-F3-2008-201889).

In collaboration with the Royal Tropical Institute the group BioSensing & Diagnostics developed a PCR - lateral flow test, the Nucleic Acid Lateral Flow ImmunoAssay (NALFIA), for the detection of specific malaria amplicons. The 4-lines NALFIA detected Pan-Plasmodium (all Plasmodium species), P.vivax, P.falciparum and a human gene specific amplicons (test control). The test was evaluated in several human trials in Africa and Asia (Mens et al., 2012a,b).

A NALFIA for the detection of single nucleotide polymorphisms (SNPs) in relation to resistance to drug combination therapy was developed as well (Moers et al., 2015)


Layout of the malaria NALFIA (first) and part of a lab trial by dr. Rachel Hallett from the London School of Hygiene and Tropical Medicine (second).